Nadda said India will need to front load its investments substantially to almost double the number of people on ARV treatment in less than five years. “We are well aware of the role that generic pharmaceutical manufacturers from India have played in initiating anti-retroviral (ARV) treatment for over 17 million people by providing affordable and high quality ARV drugs. “We have plans to increase access to high quality ARV treatment through our public health system in collaboration with the private sector and community based organisations,” he said on Thursday. India’s recently adopted Intellectual Property Rights Policy states that the country will continue to utilise the legislative space and flexibilies available in international treaties and the TRIPS Agreement. Union Health & Family Welfare Minister J P Nadda addressing the United Nations General Assembly (UNGA) high level meeting on HIV/AIDS in New York.

Source: Indian Express June 10, 2016 09:00 UTC